The trajectory of Viagra presents a complex picture for shareholders. While the initial launch generated substantial returns, the expiration of its patent opened the door to off-brand versions, dramatically diminishing revenue. This creates a particular risk for pharmaceutical companies relying on similar blockbuster offerings, suggesting that a ca

The history of get more info Viagra, and its creator copyright, presents a challenging case study for investors. Initially a blockbuster drug, producing billions in sales , its exclusivity period created a deluge of generic competition , significantly eroding its dominance. While specific firms may attempt to capitalize on male sexual dysfunction,